Summit Therapeutics co-CEO’s spouse acquires 300K shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Summit Therapeutics Inc. reported that the spouse of Co-Chief Executive Officer Robert W. Duggan exercised an option for 300,000 common shares at $1.06 per share on November 20, 2026. The spouse’s reported common-share position after the exercise was 831,000 shares, and the option expires June 28, 2032. Duggan disclaims beneficial ownership of the acquired securities except to the extent of his pecuniary interest.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F1, F3 | 300,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 300,000 | $1.06 | $318K |
| Holding | Common Stock | -- | -- | -- |
| Holding | Common Stock F2 | -- | -- | -- |
| Holding | Common Stock F2 | -- | -- | -- |
| Holding | Common Stock F2 | -- | -- | -- |
Footnotes (3)
- F1. On November 20, 2026, the Spouse of Reporting Person exercised an option to purchase 300,000 shares of the Issuer's common stock at an exercise price of $1.06 per share.
- F2. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
- F3. The option was granted to the Spouse of Reporting Person on June 28, 2022, subject to certain performance criteria. On August 23, 2024, based on satisfaction of certain performance criteria, the option vested as to 260,000 shares. On April 29, 2025, the option was modified to require only the service-based vesting requirements to continue to be satisfied in order to become fully vested; the option vested as to 520,000 shares on April 29, 2025 and the remaining 520,000 will vest in three equal annual installments, with the first such installment having occurred on October 13, 2025.
Key Figures
Key Terms
exercise price financial
beneficial ownership regulatory
pecuniary interest regulatory
performance criteria technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does SMMT’s filing say about the option’s vesting schedule?
When does the SMMT option expire?
AI-generated analysis. How Rhea-AI works. Not financial advice.